BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 8862962)

  • 1. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
    Hackelsberger A; Malfertheiner P
    Drug Saf; 1996 Jul; 15(1):30-52. PubMed ID: 8862962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Helicobacter pylori infection: a review of the world literature.
    van der Hulst RW; Keller JJ; Rauws EA; Tytgat GN
    Helicobacter; 1996 Mar; 1(1):6-19. PubMed ID: 9398908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.
    Markham A; McTavish D
    Drugs; 1996 Jan; 51(1):161-78. PubMed ID: 8741237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure.
    Mak SK; Loo CK; Wong PN; Lo KY; Tong GM; Lam EK; Wong AK
    Singapore Med J; 2003 Feb; 44(2):74-8. PubMed ID: 14503780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
    Gisbert JP; Boixeda D; Martín de Argila C; Redondo C; Moreno L; Abraira V; García Plaza A
    Med Clin (Barc); 1998 Jan; 110(1):1-5. PubMed ID: 9527978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
    Scott BB
    Aliment Pharmacol Ther; 1998 Mar; 12(3):277-9. PubMed ID: 9570263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
    Avidan B; Melzer E; Keller N; Bar-Meir S
    Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies.
    Van Oijen AH; Verbeek AL; Jansen JB; De Boer WA
    Aliment Pharmacol Ther; 2000 Aug; 14(8):991-9. PubMed ID: 10930892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of Helicobacter pylori infection.
    Hunt RH
    Am J Med; 1996 May; 100(5A):42S-50S; discussion 50S-51S. PubMed ID: 8644782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies for Helicobacter pylori infection.
    Damianos AJ; McGarrity TJ
    Am Fam Physician; 1997 Jun; 55(8):2765-74, 2784-6. PubMed ID: 9191460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
    Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori therapy: first-line options and rescue regimen.
    Gisbert JP; Pajares JM
    Dig Dis; 2001; 19(2):134-43. PubMed ID: 11549823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.